



národní
úložiště
šedé
literatury

Detailed Investigation of Human Galectins -1 and -3 by employing selectively deoxyfluorinated N-acetyllactosamines

Kurfiřt, Martin
2023

Dostupný z <http://www.nusl.cz/ntk/nusl-526202>

Dílo je chráněno podle autorského zákona č. 121/2000 Sb.

Tento dokument byl stažen z Národního úložiště šedé literatury (NUŠL).

Datum stažení: 27.09.2024

Další dokumenty můžete najít prostřednictvím vyhledávacího rozhraní nusl.cz .

Detailed Investigation of Human Galectins -1 and -3 by employing selectively deoxyfluorinated *N*-acetylglucosamines

Student: Ing. Martin Kurfiřt
Supervisor: Mgr. Jindřich Karban Ph. D.

Human galectins (hGals) are carbohydrate-binding proteins playing key roles in a plethora of physiological processes. They are able to modulate immune responses and neoplastic transformation processes via the molecular recognition of galactoside-containing glycans.¹ As a result, the development of their selective inhibitors has become a focus of pharmaceutical research. However, the preparation of inhibitors targeting individual hGals remains challenging as 12 hGals featuring similar substrate specifications have been identified. A deeper understanding of the differences between individual hGals could facilitate the development of galectin inhibitors, and deoxyfluorinated carbohydrates are established tools capable of providing such valuable information.²

This work is focused on a detailed investigation of supramolecular recognition events between human galectins -1 and -3 and mono-deoxyfluorinated *N*-acetylglucosamine probes, which were previously prepared in our laboratory.³ The recognition was studied using a combination of X-ray crystallography, isothermal titration calorimetry and several advanced NMR techniques, such as ¹⁹F T2-filter, ¹H-¹H STD, ¹H-¹⁵N CSP or ¹⁹F EXSY. These techniques provided insight into the thermodynamics and kinetics of recognition and enabled us to uncover of subtle differences between both investigated galectins. Such differences could be potentially exploited in the selective targeting of individual galectins with important implications for the galectins-focused pharmaceutical industry.

Support from MEYS (Project No. LTC20052 and LTC2007 2, COST Action CA18103 INNOGLY) and Czech Science Foundation (grant no. 20-01472S) is acknowledged. The author also thanks Jesús Jiménez-Barbero (CIC bioGUNE, Bilbao, Spain), Cañada Vicinay Francisco Javier (CIB, Madrid, Spain) and Roman Hrstka (RECAMO, Brno, The Czech Republic) for sharing expertise in NMR-based molecular recognition and providing human galectins.

References

1. Dings, R. P. M.; Miller, M. C.; Griffin, R. J.; Mayo, K. H. *Int. J. Mol. Sci.* **2018**, *19*, 905–926.
2. Linclau, B; Ardá, A.; Reichard, N.; Sollogoub, M.; Unione, L.; Vincent, S. P.; Jiménez-Barbero, J. *Chem. Soc. Rev. J.* **2020**, *49*, 3863–3888.
3. Kurfiřt, M.; Dračinský, M.; Červenková Šťastná L., Cuřínová, P.; Hamala, V.; Hovorková, M.; Bojarová, P.; Karban, J. *Chem. Eur. J.* **2021**, *27*, 13040–13051.